T0	Participants 70 85	uveal melanoma:
T1	Participants 389 404	uveal melanoma.
T2	Participants 534 687	from August 2010 through December 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada.
T3	Participants 702 757	One hundred one patients were randomized in a 1:1 ratio
T4	Participants 1113 1251	analysis, 19 patients were registered and 18 treated with selumetinib without randomization to complete the planned 120-patient enrollment
T5	Participants 2556 2609	hypothesis-generating study of patients with advanced